文献速递血栓与止血

因子V Leiden或凝血酶原G20210A基因突变患者在接受静脉血栓栓塞症延长抗凝治疗时的大出血风险

The risk of major bleeding in patients with factor V Leiden or prothrombin G20210A gene mutation while on extended anticoagulant treatment for venous thromboembolism.
PubMed 文献 · J Thromb Haemost · 2022-12-30

多中心前瞻性队列研究纳入2260例基因检测的静脉血栓栓塞症后长期抗凝成人,中位随访3年,主要出血事件106例(颅内17例、致死7例);FVL携带者与野生型大出血风险无显著差异(HR 0.89),PGM突变携带者与野生型差异亦无统计学意义(HR 0.53);多因素分析显示FVL和/或PGM突变者大出血或临床相关非大出血风险低于双野生型(HR 0.73)。

要点

  • FVL携带者与野生型大出血风险无显著差异(HR 0.89,95%CI 0.53-1.49)。
  • PGM突变携带者与野生型大出血风险差异无统计学意义(HR 0.53,95%CI 0.19-1.43)。
  • FVL和/或PGM突变者大出血或临床相关非大出血风险低于双野生型(HR 0.73,95%CI 0.55-0.97)。

核心结论

  • 血栓形成倾向(定义为存在FVL或凝血酶原G20210A突变)与静脉血栓栓塞症延长抗凝治疗期间较低的大出血/临床相关非大出血发生率相关。

研究设计与样本

  • 多中心、跨国、前瞻性队列研究,评估静脉血栓栓塞症事件后接受长期抗凝治疗的成人。

主要发现

  • 2260例接受基因检测的患者中,中位随访3年期间106例发生大出血事件(颅内17例、致死7例)。
  • 439例FVL携带者中19例发生大出血,任何突变与野生型比较无差异(HR 0.89,95%CI 0.53-1.49,p=0.66)。
  • 158例任何PGM突变(杂合或纯合)患者与野生型比较,大出血事件差异无统计学意义(HR 0.53,95%CI 0.19-1.43,p=0.21)。
  • 多因素分析显示,FVL和/或PGM突变患者较因子V和凝血酶原基因双野生型患者大出血或临床相关非大出血风险更低(HR 0.73,95%CI 0.55-0.97,p=0.03)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Thrombophilia predisposes to venous thromboembolism (VTE) because of acquired or hereditary factors. Among them, it has been suggested that gene mutations of the factor V Leiden (FVL) or prothrombin G20210A mutation (PGM) might reduce the risk of bleeding, but little data exist for patients treated using anticoagulants. OBJECTIVES: To assess whether thrombophilia is protective against bleeding. METHODS: This multicentre, multinational, prospective cohort study evaluated adults receiving long-term anticoagulants after a VTE event. We analyzed the incidence of major bleeding as the primary outcome, according to the genotype for FVL and PGM (wild-type and heterozygous/homozygous carriers). RESULTS: Of 2260 patients with genotype testing, during a median follow-up of 3 years, 106 patients experienced a major bleeding event (17 intracranial and 7 fatal). Among 439 carriers of FVL, 19 experienced major bleeding and there were no differences between any mutation vs wild-type (hazard ratio [HR], 0.89 [0.53-1.49]; p = .66). The comparison of major bleeding events between the 158 patients with any-PGM mutation (heterozygous or homozygous) vs wild-type also showed a nonstatistically significant difference with HR of 0.53 (0.19-1.43), p = .21. However, multivariate analysis demonstrated that major bleeds or clinically relevant nonmajor bleeding were statistically less likely for patients with either FVL and/or PGM compared with patients with both wild-type factor V and prothrombin genes (HR, 0.73; 95% CI = 0.55-0.97; p = .03). CONCLUSION: This study demonstrates that thrombophilia, defined as the presence of either FVL or the prothrombin G20210A mutation, is related with a lower rate of major/clinically relevant nonmajor bleeding while on anticoagulants in the extended treatment for VTE.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Caiano L, Kovacs MJ, Lazo-Langner A, et al. The risk of major bleeding in patients with factor V Leiden or prothrombin G20210A gene mutation while on extended anticoagulant treatment for venous thromboembolism. J Thromb Haemost. 2022. PMID: 36710196. doi:10.1016/j.jtha.2022.12.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。